Emerging Drugs and Targets for Parkinson's Disease

Inbunden, Engelska, 2013

3 709 kr

Beställningsvara. Skickas inom 5-8 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Affecting over 1.5 million people across the world, Parkinson's disease is a progressive neurological condition characterized, in part, by the loss of dopaminergic neurons in the substantia nigra pars compacta. It affects 1.5% of the global population over 65 years of age. As life expectancy is increasing, over the next few years the number of patients with Parkinson´s disease will grow exponentially. To date, there are no available treatments that are capable of curing Parkinson´s disease, and the current goal of therapy, dopamine replacement strategies, is to reduce symptoms. After several years of disease progression, treatment is complicated by the onset of motor fluctuations and dyskinesias. This information reveals the great importance and social need of finding an effective therapeutic intervention for Parkinson´s disease. This exemplary new book reviews some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets currently undergoing the validation process to try to reach the Parkinson´s drug market in the next few years as potential disease modifying drugs. Providing up to date and comprehensive coverage, this book is essential reading for researchers working in academia and industry in any aspect of medicinal chemistry or drug discovery.

Produktinformation

Utgivningsdatum2013-07-29
Mått156 x 234 x 28 mm
Vikt724 g
FormatInbunden
SpråkEngelska
SerieDrug Discovery Series
Antal sidor402
FörlagRoyal Society of Chemistry
ISBN9781849736176

Tillhör följande kategorier

Professor Martinez is a Research Professor at Instituto de Química Médica-CSIC. She has active research lines in the design and synthesis of new drugs for neurodegenerative diseases, searching for new targets to treat these devastating diseases. Currently, she ledas an interdisciplinary research group directed towards the discovery and development of new drugs for innovative targets in neurodegenerative disorders such as Alzheimer's Disease, Parkinson's Disease, Amyotrophic lateral sclerosis or Multiple Sclerosis.Dr Gil obtained her PhD in Pharmaceutical Sciences from Universidad Complutense de Madrid before working with Prof. Dr. Stefan Bräse in the Kekulé Institute for Organic and Bioorganic Chemistry at the University of Bonn (Germany) where she was involved in the development of T1 triazene linker that has been successfully used as a linker for arenes. During this time she was a Marie Curie fellow of the European Union. She is currently working at the Instituto de Química Médica-CSIC, where she is responsible for the design and synthesis of biologically active organic molecules in the neurodegenerative field.

Overview on Parkinson disease. Rational for pharmacological intervention;Dopaminergic pathway and L-Dopa treatments. Future challenges;COMT Inhibitors: present problems and relevance of the new ones;MAO inhibitors for PD (Safinamide);Dopamine agonist: present and future (Pardoprunox);Therapies for dopaminergic-induced dyskinesias in Parkinson disease. (Fipamizole);Beyond the dopamine receptor: regulation of protein phosphatases;Molecular chaperones as rational drug targets for Parkinson's disease therapeutics;Alpha-synuclein assembly as a therapeutic target of PD;Alpha-synuclein (alpha-syn) phosphorylating polo-like kinase 2 (PLK2) as target for PD;Hsp70 molecular chaperones and Parkinson's disease;Glutamate receptors as therapeutic targets for Parkinson's disease;Targeting adenosine A2A receptors in Parkinson's disease;Leucine-rich repeat kinase-2 as target for Parkinson's disease;Phosphodiesterase inhibitors for PD treatment;P2X7 purinergic receptor: role in neurological disorders;Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease;D3 dopamine receptor agonists: neuroprotection in Parkinson's disease;Antioxidants and PD;Tryptophan metabolism in Parkinson's disease;Grafted neural stem cell-derived dopaminergic neurons for PD Therapy;Gene therapy for Parkinson's disease;Carotid body autotransplantation in Parkinson disease;Neurotrophic factor therapy for Parkinson's disease

"The introductory chapters describingn the current state of knowledge on pathogenesis, pathophysiology, symptoms, unmet medical needs, and new therapeutic targets are excellent." "The following new approaches are covered in some detail: protein phosphatases, a-synuclein, glutamate receptor subtypes, LRRK2 kinase, phosphodiesterases, serotonin 5-HT1A receptor, tryptophan metabolism, P2X7 purine (ATP) receptor, carotid body transplantation, and stem-cell therapy. This appears to present a subjective selection of potentially important targets for future AD therapeutics." "Altogether, I can recommend this volume of the excellent RSC Drug Discovery Series to medicinal chemists, (chemical) biologists and pharmacologists interested in drug development for Parkinson’s disease."